Modern approach to basal-bolus therapy with glargine and glulisine insulin analogues in various age groups

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

DCCT (Diabetes Control and Complications Trial) study established that intensified insulin therapy in multiple daily injections (MDI) or continuous insulin infusion (CSII) regimens substantially reduce both development and progression of complications in patients with type 1 diabetes mellitus (T1DM) as compared to conventional insulin therapy. Insulin analogues possess better pharmacokinetic and pharmacodynamic characteristics than unmodified human insulin agents. These characteristics are beneficial for management of diabetes mellitus, allowing better glycemic outcomes with lower incidence of hypoglycemia. Current review discusses specifics of therapy with glargine (Lantus®) and glulisine (Apidra®) insulin analogues. Authors analyzed available to date results from corresponding clinical trials in children, adolescents and adults. Pharmacoeconomic aspects and matters of dosage of glargine and glulisine are further addressed.

Cite

CITATION STYLE

APA

Volevodz, N. N., Laptev, D. N., & Shestakova, M. V. (2013). Modern approach to basal-bolus therapy with glargine and glulisine insulin analogues in various age groups. Diabetes Mellitus, (1), 83–90. https://doi.org/10.14341/2072-0351-3602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free